As patients live longer, new criteria needed for prostate cancer trials

A lack of cancer progression could be used as a substitute for overall survival in metastatic hormone-sensitive prostate cancer clinical trials, according to a new meta-analysis published in the Journal of Clinical Oncology, an approach that could accelerate research and allow new treatments to reach patients faster.

This post was originally published on this site

Lawyers Lookup -